Full Name
Dr Lorenzo Corsini
Job Title
BioNTech R&D (Austria)
Company
Managing Director
Speaker Bio
Lorenzo is co-founder and co-CEO of PhagoMed, a biotech company developing targeted antimicrobials to treat microbiome-related conditions based on endolysins. From 2008 to 2017, he worked for the Boston Consulting Group. In his latest function as a Principal, he was advising pharmaceutical companies on topics ranging from corporate strategy to efficiency and quality in manufacturing, and leading large teams of consultants across multiple projects. Before, he did his PhD in molecular biology at EMBL Heidelberg. Lorenzo has diploma degrees in biochemistry and business administration.
Speaking At
The engineered Gardnerella endolysin PM-477 as a potential breakthrough microbiome therapy for recurrent bacterial vaginosis
ε2-phages and the cocktail PM-399: non-wild-type, non-GMO phages with vastly improved pharmaceutical properties against S. aureus
Roundtable 7: Engineering phage endolysins to treat recurrent bacterial vaginosis
ROUNDTABLE 5: Optimizing wild-type phages through recombination to create drug-grade ε²Phages®
PANEL: Concluding Thoughts from the Phage Futures Congress 2021
ε2-phages and the cocktail PM-399: non-wild-type, non-GMO phages with vastly improved pharmaceutical properties against S. aureus
Roundtable 7: Engineering phage endolysins to treat recurrent bacterial vaginosis
ROUNDTABLE 5: Optimizing wild-type phages through recombination to create drug-grade ε²Phages®
PANEL: Concluding Thoughts from the Phage Futures Congress 2021
